Month: May 2022

The pipeline for wound healing technologies includes lasers that kill bacteria and fluorescence imaging to aid in diagnostics.

 

FREMONT, CA: A skin wound is typically considered to be of little concern to the average person; however, a variety of disorders can cause or contribute to the severity of a wound that necessitates the use of specific technologies for proper healing.

Patients are predisposed to chronic wounds due to underlying factors ranging from malnutrition and stress to metabolic syndrome, necessitating intervention to accelerate a sluggish healing process.

In the United States, 3 percent of the population over the age of 65 has open wounds, and 2 percent of the entire population suffers from chronic wounds, according to a recent scholarly article that examined the magnitude of the problem.

Medicare cost forecasts for all wounds, including costs for infection treatment, range from $28.1 billion to $96.7 billion, with surgical wounds and diabetic ulcers being the most expensive to treat … read more

Treatment with the experimental protein replacement therapy PTR-01 promoted wound healing and decreased pain in people with recessive dystrophic epidermolysis bullosa (RDEB), new results from a Phase 2 clinical trial show.

The findings were presented by BridgeBio Pharma and its affiliate, Phoenix Tissue Repair, the therapy’s developer, at the annual meeting of the Society for Investigative Dermatology, in Portland, Oregon in May.

“In patients with recessive dystrophic epidermolysis bullosa (RDEB) even minor friction or trauma can cause debilitating blistering, tearing and scarring of the skin, along with severe pain … read more

Advancements in technology has helped healthcare enterprises deliver better wound care over the past few years.

 

Long-term care (LTC) wound management can provide a number of problems in achieving the ultimate aim of complete wound healing. Pressure ulcers, ischemic ulcers, venous ulcers, and diabetic foot (neuropathic) ulcers are all common conditions that healthcare providers see and treat. The risk of developing an ulcer should be examined in all residents. If a person is at high risk for developing an ulcer, staff should take aggressive measures such as nutritional support or pressure reduction. If an ulcer forms, the main goal is to heal it fully as soon as feasible and at a fair cost. Providers should distinguish between pressure, ischemia, venous, and neuropathic ulcers, keeping in mind that they might be combined and contain two or more components. Providers should assure appropriate foundational care, adequate nutrition, proper blood supply, edoema control, and great topical wound care in order to attain this goal. Topical wound care promotes wound healing by moisturizing the area and reducing necrotic tissue … read more

Researchers at the Technical University of Munich (TUM) have developed a film that not only protects wounds similar to the way a bandage does, but also helps wounds to heal faster, repels bacteria, dampens inflammation, releases active pharmaceutical ingredients in a targeted manner and ultimately dissolves by itself. This is all made possible by its dedicated design and the use of mucins, molecules which occur naturally in mucous membranes … read more

Diabetic foot ulcers (DFUs) are open sores or wounds caused by a combination of factors that include neuropathy (lack of sensation), poor circulation, foot deformities, friction or pressure, trauma, and duration of diabetes with complication risks. DFUs occur in 34% of people with diabetes,1 and approximately 14% to 24 % of patients with diabetes who develop a DFU will require an amputation … Diabetic complications cause 40% to 60% of nontraumatic lower limb amputations worldwide, and 80% of these amputations follow DFUs.2 However, a DFU is a preventable condition, despite being the leading cause of nontraumatic lower extremity amputations in the United States … read more

The role of wound cleansing in the management of wounds

 

This 30-minute presentation features learning opportunities that will provide in-depth instruction and demonstration in wound care treatments. After this webinar, the learner will be able to:

Identify the role of proper wound cleansing
Discuss how to select and use non-toxic wound cleansers
Describe advantages of collagen for managing a chronic wound
… read more

Researchers from the University of Tsukuba show that antibiotic resistance can be transferred between Staphylococcus bacteria by a process known as natural transformation … A bacteria called Staphylococcus aureus is widespread and generally harmless, but can cause infections known as “opportunistic infections”. These occur when the bacteria take advantage of certain situations, such as a weakened immune system or the presence of an open wound, to cause a harmful infection. These infections become particularly dangerous when the bacterial strain is resistant to treatment with antibiotics. Strains of Staphylococcus aureus known as MRSA, which are resistant to an antibiotic called methicillin, are becoming a significant problem worldwide. Now, a team from the University of Tsukuba have revealed the mechanism by which this methicillin resistance can be passed between bacteria … read more

providing the highest quality human tissue allografts available. We demonstrate our commitment to quality by collecting data from patient outcomes and analyzing the data for statistical significance, ensuring physicians make the most informed decision for the health of their patients. With the goal of addressing the root cause, rather than masking the pain, Regenative Labs birth tissue allografts provide an effective, non-addictive, non-invasive option for patients in debilitating situations.

 

Submit your contact information below and a representative will reach out shortly. Are you ready to create a new account? Click here to signup (please list Wound Care Weekly in the distributor field).

 

• Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus.
• Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU.
• DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation.
• Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation.
• Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life.

… read more

BY BECKY DEY – from OCTOBER 2018

 

A wound dressing made from the silk protein sericin can help skin recover without scar tissue forming, new research shows … Millions of people worldwide suffer serious skin wounds caused by burns or trauma that are unable to self-heal. The main complication surrounding skin regeneration is scar tissue, which has different functional and mechanical properties to normal physiological tissue, often causing pain and discomfort for those affected … read more

Building on the previous success of education and awareness activities, Hamad Medical Corporation (HMC) recently joined the American Diabetic Awareness Alert Day to promote Diabetic Limb Salvage and launch a nationwide Awareness Campaign themed ‘Early diagnosis leads to early intervention: save a leg, save a life’ … The initiative was aimed at educating the general public and specifically diabetic patients at risk of feet ulcers and leg amputation, increasing their knowledge of signs and symptoms of this disease, and encouraging them to take care of their own feet … Diabetic foot is a substantial public health issue that affects people worldwide. Statistics show that twenty-five percent of people with diabetes are at risk of developing diabetic foot ulcers (DFUs). Limb salvage is the endeavour to save a limb from amputation, such as the foot … read more

BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon … read more

GREENVILLE, S.C., May 18, 2022 /PRNewswire/ — A revolutionary temperature and pressure (TAP) sensing insole for diabetics, created by XtremedX, was recently named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne (DCB) in Berne, Switzerland. This is an international competition with the winners chosen by a panel of judges who are leading experts in diabetes care. XtremedX’s TAP sensing insole was one of only two products selected from the US as a leading innovative device for the management of diabetes.

 

Failure to heal a diabetic foot ulcer is a leading cause of hospitalization, amputation, disability, and death among people with diabetes. XtremedX TAP sensing insole for diabetics helps with daily monitoring of the feet, which can reduce diabetic foot ulcers by up to 85%. The sensor detects differences over time between both feet. Accumulated data from the sensor is then sent to the patient, caregiver, and/or physician via Bluetooth, Wi-Fi, or cellular technology for monitoring. An alert is provided by the insole at the first sign that an ulcer could potentially develop – often 4-6 weeks before the onset of symptoms. This allows the patient to take preventative measures to avoid an ulcer or further complications including amputation of lower extremities.

 

“We’re honored that we’ve been selected by the Diabetes Center Berne for this innovation challenge among all of the other incredible ideas and inventions to improve diabetes care,” said Carl Marshbanks, CEO of XtremedX. “It’s been an exciting time for our team, as we also recently were recognized as a first-place winner of the WeaRAcon 2022 international wearable robotics association conference this year. We’ve set out to create a product that will truly impact the management of diabetes and we’re glad to see that leaders in our industry believe in our mission as well.”

 

Each of the 20 companies with devices selected by Diabetes Center Berne participated in a pitch round this May where they presented their devices to a panel of DCB judges. These judges will select the top three finalists to participate in a bootcamp taking place on June 20 – 24 in Switzerland to develop their ideas with the help of the experts at DCB. After the bootcamp, a winner will be chosen on November 30 to be awarded $100,000 to fund further development of their innovation.

 

Diabetes Center Berne was created to advance diabetes care by bringing together some of the world’s leading experts to drive thought and innovation and provide access to clinical research facilities, laboratories, workspaces, and financial resources. Their innovation challenge provides an opportunity for companies with forward thinking ideas from around the world to make the greatest impact on the future of diabetes management.

 

ABOUT XTREMEDX

XtremedX LLC strives to develop the most technically advanced products, improving the quality of patient’s lives. They innovate technologically advanced products for Orthopedics, Surgery, DME (Durable Medical Equipment), and Smart Sensor Technology. Their mission is to create products that help to improve patient outcomes and reduce overall health care costs. As a Top Biomechanics Solutions Provider of 2021, they are also named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne, and a recipient of first-place award at the international wearable robotics association conference, WeaRAcon 2022. For more information, please visit www.xtremedx.com.

 

ABOUT DIABETES CENTER BERNE

Diabetes Center Berne is a private, independent Swiss foundation established in 2017. It helps research projects and business ideas to grow. Based in Switzerland, DCB provides expertise, access to clinical research facilities and its own laboratories and workspaces, and funding to projects around the world. It is located on the Insel Campus in the Swiss capital Bern. DCB works in close scientific partnership with the Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism of the Inselspital Bern (UDEM), a university hospital with a stellar international reputation in the field of diabetes technology.

 

Diabetes Center Berne
Freiburgstrasse 3
CH-3010 Bern
www.dcberne.com

 

SOURCE XtremedX

This article was originally published here

Longtime Congresswoman and former President and CEO of the Better Medicare Alliance, Allyson Schwartz, also joins Podimetrics’ Advisory Board

 

SOMERVILLE, Mass., May 12, 2022 /PRNewswire/ — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced four new leadership hires aimed at helping the company scale and support even more health plans and providers serving patients living with complex diabetes: Matthew Scalo as Chief Financial Officer, Kyle Bray as Chief Operating Officer, Kim Nguyen as Vice President of Financial Planning and Analysis, and Elizabeth Hogan Hamacher as Vice President of Clinical Services and Support. Podimetrics also added a new member to their advisory board, Allyson Schwartz, a long-time Congresswoman and also the former President and CEO of the Better Medicare Alliance.

 

These key hires and advisory board appointment follow Podimetrics’ recent announcement of their Series C. The company also experienced unprecedented growth in 2021, including doubling the patients under management with the Veterans Health Administration; doubling revenue for the third year in a row; and also doubling the size of the Podimetrics team. Dr. Jon Bloom, CEO and co-founder of Podimetrics, shared the following insights on the company’s growth trajectory for the year ahead: “We are in high-growth mode, and these leadership hires and the appointment of Allyson Schwartz to Podimetrics’ advisory board reinforce our focus on helping even more at-risk, underserved patients avoid the unnecessary health toll and financial burden associated with amputations resulting from complex diabetes.”

 

In just the first quarter of 2022, Podimetrics rounded out their leadership team with a series of strategic new hires that position the company for strong growth in the year ahead:

 

• Matthew Scalo, Chief Financial Officer — With nearly two decades of experience spanning banking and financial services, he most recently served as the senior vice president of finance at Cancer Treatment Centers of America;
• Elizabeth Hogan Hamacher, Vice President of Clinical Services and Support — A registered nurse with more than 12 years of clinical operations experience, she most recently served as senior director of clinical operations at ConsumerMedical; and
• Kim Nguyen, Vice President of Financial Planning and Analysis — With more than a decade of experience, she most recently served as associate vice president for financial planning and analysis for vRad (Virtual Radiologic).

 

The company’s latest addition to their advisory board, Allyson Schwartz, also brings unprecedented experience in healthcare, as well as policy. As a former member of the House of Representatives and former President and CEO of the Better Medicare Alliance, she is a nationally recognized leader on healthcare issues and was also instrumental in the passage of the Affordable Care Act. Schwartz shared the following insights about joining the advisory board at Podimetrics: “Podimetrics serves some of our nation’s most vulnerable patients — patients who have been ignored for far too long. It’s an honor to join their advisory board. The research and innovation they are leading will help drive a new preventive and proven approach to helping reduce amputations in patients living with complex diabetes.”

 

Podimetrics invented the SmartMat, which has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans. The SmartMat is the only easy-to-use, at-home mat that a patient steps on for only 20 seconds per day. The mat detects temperature changes in the foot, which are often a precursor to diabetic foot ulcers (DFUs). Patient temperature data from the SmartMat is then remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat is indicative of potential health issues, Podimetrics’ nursing team swiftly connects both with the patient and the patients’ provider.

 

For more information on Podimetrics and how its SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit Podimetrics.com or follow us on LinkedIn and Twitter.

Contact: press@Podimetrics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podimetrics-announces-expansion-of-leadership-team-with-four-new-strategic-growth-hires-301545591.html

BY LEONARD A. LEVY, DPM, MPH (from April 2021)

 

Podiatric Medical Practice, People with Diabetes, and the Relationship to Primary Care The typical practice of podiatric medicine includes a population that receives care on a more frequent basis than perhaps most patients seen by other medical specialists (e.g. surgeon, ophthalmologist, dermatologist, and otorhinolaryngologist). Patients who receive care from podiatric physicians very often do so several times yearly and often follow such a regimen over several years. Because of this, podiatric physicians with their education and training appropriately could be among the physicians who provide a major segment of primary care … read more (PDF)

Nancy Collins, PhD, RDN, LD, NWCC, FAND

 

Nutrition is a critical factor in the wound healing process, with adequate protein intake essential to successful healing. Patients with chronic and acute wounds, such as postsurgical wounds or pressure injuries, require increased protein to ensure complete and timely healing. Older patients with multiple comorbidities present a particular challenge. They often do not consume the necessary quality and quantity of dietary protein. In addition, this population may have a heightened stress response and resultant muscle loss due to a reduction in muscle protein synthesis. The all too frequent result is compromised wound healing, decreased ability to fight infections, and longer recovery time from illnesses and surgeries. It is imperative to address the increased protein needs of patients with wounds, especially older patients, to promote a full recovery … read more

“Uncaring: How the Culture of Medicine Kills Doctors and Patients”

 

by Caroline Fife, M.D.

 

I’ve been venting about my experiences with a broken healthcare system – both as a doctor and a caregiver. My friend, colleague, plastic surgeon and Renaissance man, Dr. Aron D. Wahrman alerted me to Robert Pearl’s book, Uncaring: How the Culture of Medicine Kills Doctors and Patients (a follow up to his book, Mistreated: Why We Think We’re Getting Good Health Care — and Why We’re Usually Wrong. I’ve recently talked about the experience of my friend and patient Dr. Richard Maddy, who lost both of his legs to cutaneous polyarteritis nodosa– in part because my pleas to start high dose steroids based on his clinical presentation were ignored, and my husband who died (albeit indirectly) from an adverse drug reaction that I diagnosed but for whom I could not the proper intervention from his inpatient team … read more

Author(s): Thomas Bjarnsholt, Val Edwards-Jones, Matthew Malone, Karen Ousey, Mark Rippon, Alan Rogers, Samantha Westgate, Sabine Eming, Isabelle Fromantin, Astrid Probst, Hans Smola, Hui-Mei Yang, Jiun-Ting Yeh, Steven Percival

 

Every wound type has the potential to develop serious infection, which in some cases can lead to chronicity, bone infections, long-term disabilities or even death. Bacteria within a wound will exist in either planktonic or biofilm forms, with treatment mostly by use of topical antimicrobials or antibiotics. Alarmingly, there is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance in many common bacterial pathogens and the misuse of antimicrobial agents … read more

Chronic wound caused by diabetes is an important cause of disability and seriously affects the quality of life of patients. Therefore, it is of great clinical significance to develop a wound dressing that can accelerate the healing of diabetic wounds. Nanoparticles have great advantages in promoting diabetic wound healing due to their antibacterial properties, low cytotoxicity, good biocompatibility and drug delivery ability. Adding nanoparticles to the dressing matrix and using nanoparticles to deliver drugs and cytokines to promote wound healing has proven to be effective. This review will focus on the effects of diabetes on wound healing, introduce the properties, preparation methods and action mechanism of nanoparticles in wound healing, and describe the effects and application status of various nanoparticle-loaded dressings in diabetes-related chronic wound healing … read more

‘Best Technology Award’ and ‘Best Newcomer Award’

 

PRESS RELEASE MAY 10, 2022

DALLAS, May 10, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, has been recognized for two prestigious European technology awards.

 

Spectral MD has been shortlisted for two awards at this year’s European Mediscience Awards for:

Best Technology Award
Best Newcomer Award

 

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognizing achievements in the life sciences industry. The European Mediscience Awards recognizes success and achievement amongst both private and publicly quoted companies throughout Europe and, as such, is attended by European life science companies and their corporate advisers, analysts, fund managers, commentators and peers.

 

Nooman Haque, Managing Director, Lifescience & Healthcare, Silicon Valley Bank, commented:

“The shortlist reflects the continuing strong growth of the European Mediscience industry and, in these challenging economic times, highlights those companies best positioned to manage through the turbulent cycle. We’re delighted to see such continuing enthusiasm for the industry.”

 

Wensheng Fan, CEO of Spectral MD, said:

“We are honored that Spectral MD has received nominations for ‘Best Technology Award’ and ‘Best Newcomer Award.’ This recognition further validates the promising potential of our DeepView® Wound Imaging Technology. DeepView® has the potential to be transformative in wound care. We look forward to building on this support and the exceptional results obtained thus far to expand into other important indications for our artificial intelligence for wound healing diagnostics.”

 

The winners will be announced at the celebratory dinner, to be held at the Hotel InterContinental, London W1, on Thursday, June 16, 2022.

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

Both Planktonic Bacteria and Bacterial Biofilms

 

Highlights

• In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria)
• XPERIENCE was shown to inhibit biofilm formation for up to five hours after application
• Study published in The Journal of Arthroplasty

 

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, “A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty,” also found that XPERIENCE produced minimal cytotoxic effects to human tissue, allowing the solution to remain in the body without need for subsequent rinse. Additionally, XPERIENCE – cleared by the FDA for U.S. sale in April 2021 – was shown to inhibit biofilm formation for up to five hours after application.

 

Prosthetic joint infection (PJI) remains a significant burden in total hip arthroplasty (THA) and total knee arthroplasty (TKA) in the United States. Estimates indicate that, by 2030, the annual hospital costs related to PJI of the hip and knee will be $1.85 billion.1 Interventions to reduce or prevent the occurrence of PJI continue to be at the forefront of research efforts and commercial development.

 

“The minimum standard of care for irrigation in orthopedic surgical cases includes normal saline, but an increasing amount of literature in recent years has suggested that different solutions or additives may be needed to prevent PJI,” said orthopedic surgeon Ravi K. Bashyal, MD, the study’s lead author. “Combatting planktonic bacteria and the formation of biofilm is especially important given the high negative consequence of developing a PJI in the total joint arthroplasty setting.”

 

In the in vitro study, XPERIENCE demonstrated 4-log to 6-log reductions in planktonic bacteria after five minutes, and 4-log to 8-log reductions in biofilm bacteria. Future research using large-series in vivo data is necessary to further establish the irrigant’s efficacy in reducing primary and recurrent surgical site infections (SSIs). An estimated 1.5 million SSIs in the United States each year2 contribute $3.3 billion to the cost of U.S. healthcare.3

 

The study also found that XPERIENCE showed higher in vitro antimicrobial efficacy than three other commercially available adjuvants. The comparative treatments each reduced biofilm in all bacterial strains tested by approximately 1-log or less when the application times in their respective instructions for use were followed. However, XPERIENCE reduced biofilm by approximately 3-log to 8-log when used as directed.

 

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialization of products powered by its proprietary XBIO Technology. For further information visit: www.nextscience.com.

 

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

 

¹Premkumar A., Kolin D.A., Farley K.X., et al. “Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States.” J Arthroplasty, 2021;36(5):1484-1489 e1483.

²Darouiche, R. (2019). “Surgical Site Infections.” Retrieved from: https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/ hospital-infection-control/surgical-site-infections

³Zimlichman, E., et al. “Health Care-Associated Infections. A Meta-Analysis of Costs and Financial Impact on the US Health Care System.” JAMA Intern Med, 173(22): (2013): 2039-46.

 

Contacts
Judith Mitchell
Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

 

Anthony Priwer
Dalton Agency
Phone: +1 615-515-4891
Email: apriwer@daltonagency.com

Hidradenitis suppurativa (HS) is a chronic autoinflammatory disease characterised by recurrent painful nodules, abscesses, sinus tracts and scars at apocrine gland-bearing sites. Treatment is universally challenging and sufferers may live with chronic and recurrent draining wounds. This review provides an up-to-date, evidence-based summary of HS, including clinical features, severity assessment, disease pathogenesis and current and emerging therapeutic approaches … read more

Part two of the EWMA document ‘The impact of patient health and lifestyle factors on wound healing’ focuses on two factors: physical activity and nutrition. In this paper, the pathophysiological understanding of how physical activity and nutrition either increase the risk for wounding or impact the healing process will be presented. We review current evidence for the effectiveness of interventions in improving healing outcomes and offer some recommendations for practice and further research. This part of the document should be read in conjunction with Part 11, which discussed stress, sleep, smoking, illicit drug use and alcohol misuse and described how some commonly used medications impact the healing process … read more

The outbreak of the coronavirus disease 2019 (COVID-19) led to events that significantly impaired the treatment and management of patients with chronic diabetes. Therefore, elective treatments at hospitals were cancelled and patients with chronic ailments were instructed to stay at home and minimise the time spent in public areas. The second was due to COVID-19-induced anxiety that deterred many patients from seeking care and adhering to periodic out-patient visits. In this study, we examined the short-term effects of the COVID-19 pandemic on patients with chronic diabetes who suffered from contaminated diabetic ulcers. We conducted a retrospective study with patients who had undergone amputations following diabetic ulcers during 2019-2020. The research group included diabetic amputees during the COVID-19 outbreak period ranging from March 2020 to December 2020. The control group included diabetic amputees from the corresponding period … read more

Rates of hospitalization and major amputations among racial and ethnic minority adults with diabetic foot ulcers decreased in states that adopted Medicaid expansion under the Affordable Care Act (ACA), according to researchers at the University of Arizona Health Sciences … Diabetic foot ulceration and amputation have serious health and financial implications, and the disproportionate rate at which it occurs among patients in lower socioeconomic groups is a largely recognized issue within the fields of medicine and vascular surgery … read more

HMP Global, the omnichannel leader in healthcare events and education, today announced the launch of a new program offering professionals who treat diabetic foot syndrome the opportunity to debate the most controversial topics in treatment options and gain knowledge from one another.

 

Great Debates & Updates in Diabetic Foot will be held December 2-3 in San Antonio, Texas. The unique, debate-style format will include dynamic presentations and interactive debates, while also diving into the long history of podiatry culture in San Antonio.

 

“The agenda will feature a mix of clinical updates and lively debates on provocative scientific topics impacting the field, including emerging concepts and treatment options for the diabetic foot,” said Dr. Lawrence A. Lavery, UT professor, board-certified podiatrist at UT Southwestern Medical Center, and event co-chairman. “We are excited to lead this inaugural event and provide a unique, interactive experience to the attendees, with several opportunities to network with faculty, industry, and colleagues.”

 

This year is the 50th anniversary of the podiatry residency program at the University of Texas Health Science Center in San Antonio, Lavery said, a milestone which will be celebrated at the GDU in Diabetic Foot event.

 

“There is a rich history of podiatry culture and diabetic foot research in Texas,” said Dr. Lee C. Rogers, event co-chairman and Chief of Podiatry and Associate Professor in the Department of Orthopedics at the University of Texas Health. “The Diabetic Foot Ulcer Classification System is a proven, effective, and widely used classification system for predicting hospitalization and lower extremity amputation. We look forward to discussing this, along with other important treatment tools and techniques, during the new program.”

 

GDU in Diabetic Foot is designed for the wide spectrum of medical professionals who diagnose and manage the diabetic foot, including podiatrists, wound care physicians, physical therapists, physicians-in-training, nurse practitioners, and physician assistants. The in-person meeting will allow attendees more opportunities for networking and engaging with colleagues and faculty experts.

 

“The GDU brand offers an educational experience unlike any other,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “These unique, debate-style conferences provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in different fields. We are excited to introduce the GDU brand through important education about managing and treating the diabetic foot.”

 

GDU in Diabetic Foot offers a maximum of 9 hours of continuing education credit. Exhibit space, attendee engagement options, and branding opportunities are available to organizations interested in participating in the event.

 

For more information or to register, visit gdudiabeticfoot.com.

 

About HMP Global
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Patients with a diabetic foot ulcer who received probiotic supplementation for 12 weeks experienced faster wound healing coupled with an improved glycemic and lipid profile compared with patients assigned placebo, according to findings from a randomized controlled trial … Sima Mohseni, of the infectious diseases and tropical medicine research center at Babol University of Medical Sciences in Iran, and colleagues analyzed data from 60 adults aged 40 years to 85 years with grade 3 diabetic foot ulcer, who randomly received either probiotic supplementation (n = 30) or placebo (n = 30) daily for 12 weeks … read more

Scott Freeman, PA-C, talks post-procedure infection prevention at the current New Wave Dermatology conference.

 

Scott Freeman, PA-C, in a video for Dermatology Times®, highlighted the importance of making sure patients adhere to good wound care at the Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference being held this week in Coral Gables, Florida. Additionally, he gave pearls on infection prevention.
… watch

To Elevate Awareness Of Hyperbaric Oxygen Therapy

 

BOCA RATON, Fla., May 2, 2022 /PRNewswire/ — CūtisCare, a leader in wound care and hyperbaric management, launches its second annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy. Hyperbaric Oxygen Therapy is an effective healing option for many different chronic conditions. Still, many go years without this treatment because they are unaware of treatment indications, benefits, and the patient selection criteria of hyperbaric medicine.

 

Hyperbaric oxygen therapy (HBOT) is a proven treatment option for wounds, infections, or injuries that have not responded to standard treatment. There are currently fourteen indications for HBOT recognized by the Centers for Medicare and Medicaid Services (CMS) and other third-party payors. Hyperbaric oxygen therapy is most commonly used for the treatment of diabetic ulcers of lower extremities, radiation injury to bone or tissue, compromised grafts and flaps, and chronic refractory osteomyelitis.

 

Hyperbaric Awareness USA™ designated May Hyperbaric Awareness Month. Throughout this month (and beyond), the Hyperbaric Aware™ campaign aims to promote hyperbaric oxygen therapy benefits, which will help people prolong lives, reduce amputations, and reduce the cost of care while improving quality of life.

 

There are more than eight million people in the United States who are living with chronic wounds. Twenty-five percent of the 34 million people in the US with Diabetes will develop a foot ulcer, possibly leading to amputation. Hyperbaric oxygen therapy provides necessary oxygenation, which is critical in preventing amputation.

 

In the US, almost half of the 17 million people diagnosed with cancer will receive radiation therapy, and 10-15% will experience late effects of radiation. Many patients who undergo radiation therapy discover a hidden complication that may not come to light until years after they complete treatments. Radiation therapy can restrict oxygen in the body’s healthy tissue which is needed for the tissue to thrive. If there is a break in the integrity of the tissue, infection and non-healing wounds can occur. Hyperbaric oxygen therapy is a treatment option for patients who suffer from late radiation tissue injury stimulating the growth of new blood vessels following radiation-induced damage.

 

CūtisCare Board Chairman and CEO Jim Patrick said, “As an industry leader, we are addressing the lack of awareness of hyperbaric oxygen therapy, a critical modality for chronic wound healing and limb preservation.”

 

The Hyperbaric Aware website, in collaboration with the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders, will share articles, latest research, and expert insight for physicians, patients, and the general public.

 

About CūtisCare
Headquartered in Boca Raton, Florida, CūtisCare works with hospitals, academic medical centers, hospital systems, and physicians to design customized outpatient wound care and hyperbaric oxygen (HBOT) solutions. With more than 25 years of management experience, a commitment to research, and driven by ethics and a culture of compliance, CūtisCare collaborates with its partners to reach and heal people with chronic wounds.

 

For more information, visit https://cutiscareusa.com and https://hyperbaricaware.com

 

Follow us CutisCare LLC | LinkedIn and Hyperbaric Aware|LinkedIn.

Media Contact:

Kelly Caceres
kcaceres@cutiscareusa.com
904-446-0708
SOURCE CutisCare LLC

 

This article was originally published here

Joint provider with the South Carolina Podiatric Medical Association
Up to 20 continuing education contact hours
From $299/per night, Rate guaranteed until 05/23/22 or until room block is filled
Footprints in the Sand for Assistants: The Program will offer the ASPMA Radiology Certification Exam.
… register

available for purchase

Angela Gibson, MD, PhD, FACS, Aiping Liu, PhD, Collin L Tran, BS, Sameeha E Hassan, BS

 

Chlorhexidine (CHG) is ubiquitous in surgical perioperative care. In vivo studies of CHG cytotoxicity on human skin are lacking. Given the use of CHG for daily wound cares and as a presurgical scrub, including donor site preparation, we sought to identify if CHG cytotoxicity would persist in a clinically relevant in vivo human skin xenograft model … read more

Several iodine formulations have been used for wound care for ages, but still there exist a number of controversial issues regarding their uses in the present era. Many published studies are available for both povidone iodine (PI) and cadexomer iodine (CI) with conflicting outcomes due to different preparations used and different study types. PI has a broad spectrum of activity including antiseptic properties, anti-inflammatory properties, low cytotoxicity, and good tolerability with the absence of associated resistance. CI is an immobilized iodine molecule in a hydrophilic modified-starch polymer bead with the dual property of cleansing the wound by absorbing the exudate and bactericidal effect by sustained release of iodine molecules over the infected wound. The preparations comprising PI and CI improve wound healing and minimize the bacterial infestation or contamination in various chronic wounds, burns, and ulcers. This review narrates the comparison of CI and PI for the management of wounds in the context of biofilm reduction, wound size reduction, and granulation tissue promotion … read more